GSK Gears Up To Fight NICE On Benlysta Setback
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.
In preliminary assessment, NICE says it won't recommend GSK's Benlysta for systemic lupus erythematosus as it is too expensive, but a population subgroup analysis may be able to change the ruling.